Darya V. Demina

Darya V. Demina

Auto-generated profile, based on publicly available information

Darya V. Demina

Scientific Institution Research Institute of Fundamental and Clinical Immunology

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2021 in Russian Journal of Allergy
Verified
Journal Article
Closed access
PDF file
OBOlga S. Bodnya
Olga S. Bodnya
DDDarya V. Demina
Darya V. Demina
NKNatalia B. Kuzmenko
Natalia B. Kuzmenko
TLTatiana Latysheva
Tatiana Latysheva
TLTatiana V. Latysheva
Tatiana V. Latysheva
СПСизякина Людмила Петровна
Сизякина Людмила Петровна
Hereditary angioedema is a rare (orphan) disease associated with the development of angioedema of various localization caused by the action of bradykinin. The main symptoms of the disease are peripheral angioedema, abdominal attacks (accompanied by severe pain syndrome), edema of the upper respiratory tract, which may lead to asphyxia and death of the patient. Peripheral edema disrupts social and professional activity, the occurrence of facial edema complicates social adaptation, the unpredictability and potential threat to life of edema in the larynx, as well as the lack of effect from standard (systemic glucocorticoid and antihistamines) therapy regimens lead to a low quality of life of patients, a large number of days of disability, hospitalizations, in some cases, premature death of patients. According to international studies, on-demand therapy does not reduce the burden of the disease, and therefore international guidelines emphasize the importance of timely and individualized selection of long-term prevention for patients with hereditary angioedema. Taking into account the appearance of a new drug for long-term prevention in Russia, an Expert Council was held to assess the burden of the disease in Russian patients, determine the proportion of patients who need long-term prevention, criteria for choosing a medication for prophylaxis and the place of Lanadelumab in it.

9 July 2023 in Russian Journal of Allergy
Verified
Journal Article
Closed access
PDF file
TLTatiana Latysheva
Tatiana Latysheva
IMIrina A. Manto
Irina A. Manto
LALiubov V. Aleshina
Liubov V. Aleshina
EBElena N. Bobrikova
Elena N. Bobrikova
EVEkaterina A. Viktorova
Ekaterina A. Viktorova
ЩЮЩербина Анна Юрьевна
Щербина Анна Юрьевна
BACKGROUND: Hereditary angioedema with C1 inhibitor deficiency is a rare disease caused by a deficiency and/or a decrease in the functional activity of the C1 inhibitor. The primary symptom of this condition is recurrent angioedema of various localizations. According to the modern concept of treatment, the therapy aims to stop emerging angioedema and prevent death as well as achieve complete control of the disease and a high quality of life. Lanadelumab is a modern medicine developed and used to prevent attacks in patients with hereditary angioedema aged 12 years. AIM: A retrospective study (IISR-2021-200085) was conducted to evaluate the efficiency and safety of lanadelumab in real-life practice in Russia. MATERIALS AND METHODS: In all, 16 patients with hereditary angioedema and C1 inhibitor deficiency were enrolled at the initiation of lanadelumab treatment. The patients were predominantly female (81%; 13/16). The average age of patients was 29.9 years; 19% (3/16) of the patients were adolescents. The effectiveness was evaluated by comparing the patient-reported attack rates. The following PROs for the adults only were assessed initially and during the treatment: angioedema activity score, angioedema control test (AECT), angioedema quality of life questionnaire (AE-QoL), and hereditary angioedema activity score. The incidences of adverse events were evaluated. RESULTS: Before lanadelumab, 69% (11/16) of the patients received alternative long-term prophylaxis, which was canceled after the start of lanadelumab treatment. The average number of attacks per month and treated attacks per month prelanadelumab were 10 and 4.7 per patient, respectively. After 6 months of treatment, these values were 0.26 and 0.09, respectively (10 patients were symptom free at 6 months after the initiation of the treatment). After 3 months of treatment, the mean AECT values improved from 5.6 to 14.2 (p 0.001), and all patients showed adequate disease control. After 6 months of treatment, AE-QoL decreased from 58 to 19 (p 0.001). No serious adverse events related to lanadelumab were observed. CONCLUSION: Our study demonstrated that the composite effect of lanadelumab minimizes the attack rate and improves the quality of life in patients with hereditary angioedema. A good safety profile of lanadelumab is shown.

4 October 2026 in Russian Journal of Allergy
Verified
Journal Article
Closed access
PDF file
NINatalia I. Ilina
Natalia I. Ilina
ESEvgenia Shikh
Evgenia Shikh
OKOksana M. Kurbacheva
Oksana M. Kurbacheva
NNNatalia M. Nenasheva
Natalia M. Nenasheva
ENEvgeny V. Nosulya
Evgeny V. Nosulya
JPJulia P. Pokalyukhina
Julia P. Pokalyukhina
On March 26, 2026, a meeting of the interdisciplinary Advisory Board in the fields of allergology, otolaryngology, and pediatrics titled “Leukotriene receptor antagonists in the treatment of respiratory allergy” was held in Moscow. Allergic rhinitis is a common chronic non-infectious disease of the upper respiratory tract, characterized by symptoms that significantly impair quality of life, sleep, and work productivity. Allergic rhinitis is frequently associated with comorbid conditions — such as allergic conjunctivitis, bronchial asthma, and adenotonsillar hypertrophy — and represents a significant risk factor for the complicated course of sinusitis. Latest-generation antihistamines and intranasal glucocorticoids are the main classes of drugs with a compelling evidence base regarding their efficacy and safety in allergic rhinitis. Despite this, more than half of all patients experience uncontrolled disease progression. One of the key challenges in achieving allergic rhinitis control is poor adherence to therapy caused by various factors, the most frequent of which include inconvenient administration (both the route and the dosing regimen), side effects, and steroidophobia. Another challenge stems from intranasal anatomical features (such as a deviated nasal septum or concha bullosa/hyperpneumatization of the middle turbinate), which can impede the adequate distribution of therapeutic concentrations of intranasal drugs within the nasal cavity. Leukotriene receptor antagonists suppress inflammation of the nasal and bronchial mucosa, are effective against nasal congestion and nighttime symptoms, and can be prescribed as monotherapy or in combination with other drugs. Prescribing leukotriene receptor antagonists to patients with comorbid allergic rhinitis and bronchial asthma allows for the control of symptoms of both diseases, reduces medication burden, and prevents polypharmacy. Fixed-dose combinations (leukotriene receptor antagonists + antihistamines), which possess synergistic and complementary actions, offer advantages over monotherapy by potentiating the therapeutic effect and improving treatment adherence. When discussing the safety profile of montelukast, including its use in a fixed-dose combination with levocetirizine, the Advisory Board reached a consensus that neuropsychiatric adverse events associated with montelukast are extremely rare, and there is no direct drug-drug interaction between montelukast and levocetirizine. It was noted, that patients with allergic rhinitis frequently present with baseline psycho-emotional disturbances related to the disease. Given the rare nature of these adverse events, the safety profile of the fixed-dose combination of montelukast and levocetirizine was recognized as favorable, and the potential benefit of this combination therapy was considered high. The prescription of the fixed-dose combination of montelukast 10 mg and levocetirizine 5 mg (Montral ML) aligns with Russian federal clinical guidelines for allergic rhinitis and is recommended at any treatment step, including as initial therapy for seasonal or perennial allergic rhinitis, especially in cases of severe nasal congestion and/or co-occurrence with bronchial asthma.

30 June 2026 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Closed access
TNTatiana Nekrasova
Tatiana Nekrasova
LALiubov Aleshina
Liubov Aleshina
EBElena Bobrikova
Elena Bobrikova
EVEkaterina Viktorova
Ekaterina Viktorova
EVElena Volkova
Elena Volkova
TLTatiana Latysheva
Tatiana Latysheva
Background: Hereditary angioedema (HAE) caused by C1 inhibitor deficiency is a rare condition marked by recurrent swelling of the skin and mucous membranes. This study evaluated the effectiveness and safety of lanadelumab in routine clinical practice in Russia (IISR-2021-200085). Methods: A prospective cohort of 30 individuals with HAE was observed. Most patients were women (87%), with a mean age of 34 years; Seventeen percent of participants were adolescents. Prior to initiating lanadelumab, 16 patients (53%) had been receiving long-term prophylaxis, which was discontinued once lanadelumab was started. Treatment outcomes were assessed by comparing attack frequency, medication use for acute events, disease control scores, and quality of life before and after lanadelumab therapy. Results: Before treatment, patients reported an average of 8.6 attacks per month. After 6 months of lanadelumab treatment, the mean attack frequency was reduced to 0.5 per month (p < 0.001). Use of acute therapies decreased from 4.73 to 0.43 doses per month (p < 0.001). Disease control improved substantially, and quality-of-life scores improved from 58.2 to 25.3 points (p < 0.001). No significant lanadelumab-related adverse events were observed. Conclusion: In routine clinical practice, lanadelumab proved highly effective in reducing attack rates, enhancing disease control, and improving quality of life in patients with hereditary angioedema. The therapy was well tolerated, with no serious safety concerns identified. These findings reinforce lanadelumab as a reliable long-term prophylactic option for hereditary angioedema management.

19 October 2021 in Medical Immunology (Russia)
Verified
Journal Article
Open access
PDF file
III. P. Ivanova
I. P. Ivanova
DDD. V. Dyomina
D. V. Dyomina
MDM. N. Davydova
M. N. Davydova
GSGalina Victorovna Seledtsova
Galina Victorovna Seledtsova
The aim of this work was to study some parameters of cellular immunity in patients with multiple sclerosis (MS). The study included 10 patients with relapsing-remitting MS aged 32 to 50 years. Diagnosis was clinically established and confirmed by magnetic resonance imaging. Patients did not receive immunosuppressive therapy for at least 6 months prior to study entry. The neurological status of all examined patients was assessed using the Kurtzke functional scale using the Extended Disability Scale (EDSS) and averaged 4.0±0.67 points, the mean number of exacerbations per year was 1.25±0.25. While studying such parameters of the immune status such as the number of T, B, NK-cells, the content of immunoglobulins, the phagocytic activity of monocytes and granulocytes, their production of reactive oxygen species, no significant differences were observed in patients with MS in comparison with the normal donor level. At the same time, we have noted an increase in the proliferative response of mononuclear blood cells to myelin antigen by 2.35 times. The content of CD4+CD45RO+CD62L+ and CD8+CD45RO+CD62L+ central memory T-cells, as well as CD8+CD45RO+CD62L- effector memory T-cells in the blood of MS patients significantly exceeded the control values (p < 0.05). Also, in MS patients, compared with healthy individuals, there was an increased level of naive IFNγ-positive CD4+CD45RO- and CD8+CD45ROT-cells (p < 0.01), and an increase in CD4+CD45RO+ and CD8+CD45RO+ memory T-cells producing IFNγg or IFNγg together with IL-4 in response to the activation (p < 0.01). Consistent with these data, there were significantly increased serum IFNγ and IL-17 levels and no changes in IL-4 levels. The relative level of naive CD4+CD25+FoxP3+, as well as induced CD4+CD25- FoxP3+ regulatory T-cells in MS patients did not significantly change compared to donor values. The results of assessing some parameters of the immune status in MS patients indicate a functional reshaping of the immune system towards the Th1 type of immune response. It is obvious that immunotropic treatment of MS should be aimed at inactivating auto-immune Tand B-lymphocytes, suppressing the production of proinflammatory mediators, and enhancing the activity of natural and induced regulatory T-cells.

1 January 2022 in Immunologiya
Verified
Journal Article
Closed access
AAAlina Alshevskaya
Alina Alshevskaya
JZJulia Zhukova
Julia Zhukova
JLJulia Lopatnikova
Julia Lopatnikova
JSJu.A. Sennikova
Ju.A. Sennikova
NSN.S. Shkaruba
N.S. Shkaruba
NFNovosibirsk State Medical University of the Ministry of Health of the Russian Federation
Novosibirsk State Medical University of the Ministry of Health of the Russian Federation
Однонаправленные и разнонаправленные изменения в экспрессии мембраносвязанных рецепторов к ФНО на иммунокомпетентных клетках при ревматоидном артрите